share_log

GlaxoSmithKline | 6-K: Viiv Healthcare Presents Phase I Clinical Trial Findings of a Cabotegravir Long-Acting Injectable Investigational Formulation Allowing at Least Four Months Between Doses

SEC announcement ·  Mar 5 06:13
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more